In the last decade an increasing body of research has focussed on the potential role of inflammation in the onset of psychiatric disorders. Although the association between inflammation and depression appears now widely acknowledged, mixed findings have been reported in psychosis leaving the pathophysiological role of inflammation in psychosis still unclear. This paper aims to review studies focussing on inflammation in first-episode psychosis, in order to avoid the possible confounding effects of the long duration of illness and chronic treatment with psychotropic medications. Increased levels of IL-6, TNF-α and IL-1β are the most consistent findings from the studies conducted in first-episode psychosis patients. Mixed findings on other cytokines could be partly due to the different methodologies of the studies reviewed. The findings on the association between inflammatory markers and clinical symptoms and physical health, as well as on the effect of antipsychotic medications on inflammation at the onset of psychosis are also reviewed and discussed. The increased inflammation at onset of psychosis as well as in other psychiatric conditions, such as depression, suggests the presence of biological abnormalities which play a pathophysiological role across different diagnostic categories. Future research should test if increased inflammation could be used for the development of biomarkers, as well as as a potential therapeutic target for different subsamples of patients independently of their diagnostic category.

Keywords:
Inflammation, Psychosis, Schizophrenia, Cytokines, Inflammatory marker, Biomarker
1.
Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 2001;933:222-234.
2.
Cohen H, Liberzon I, Richter-Levin G: Exposure to extreme stress impairs contextual odour discrimination in an animal model of PTSD. Int J Neuropsychopharmacol 2009;12:291-303.
3.
Gill J, Vythilingam M, Page GG: Low cortisol, high DHEA, and high levels of stimulated TNF-α, and IL-6 in women with PTSD. J Trauma Stress 2008;21:530-539.
4.
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
5.
Zunszain PA, Hepgul N, Pariante CM: Inflammation and depression. Curr Top Behav Neurosci 2013;14:135-151.
6.
Haroon E, Raison CL, Miller AH: Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-162.
7.
Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N, Miorelli A, Navari S, Papadopoulos AS, Aitchison KJ, Morgan C, Murray RM, Dazzan P, Pariante CM: Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 2011;72:1677-1684.
8.
Aiello G, Horowitz M, Hepgul N, Pariante CM, Mondelli V: Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with ‘at risk' mental state. Psychoneuroendocrinology 2012;37:1600-1613.
9.
Belvederi Murri M, Pariante CM, Dazzan P, Hepgul N, Papadopoulos AS, Zunszain P, Di Forti M, Murray RM, Mondelli V: Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 2012;37:629-644.
10.
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011;70:663-671.
11.
Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
12.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
13.
Capuron L, Poitou C, Machaux-Tholliez D, Frochot V, Bouillot JL, Basdevant A, Laye S, Clement K: Relationship between adiposity, emotional status and eating behaviour in obese women: role of inflammation. Psychol Med 2010;41:1517-1528.
14.
Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J: Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579.
15.
Ryan MCM, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289.
16.
Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH: The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74:1999-2008.
17.
Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM: Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors' and longitudinal ‘targets'. Neuropsychopharmacology 2013;38:377-385.
18.
Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L, Murray RM, Dazzan P, Pariante CM, Mondelli V: Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun 2013;31:90-95.
19.
Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP: The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 2009;65:481-488.
20.
Kubistova A, Horacek J, Novak T: Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 2012;24(suppl 1):S153-S156.
21.
Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, Esmatjes E, Garcia-Rizo C, Kirkpatrick B: Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009;194:434-438.
22.
Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, Stefanis CN: Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001;47:13-25.
23.
Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, Pelayo-Teran JM, Fernandez-Prieto L, Leyva-Cobian F, Vazquez-Barquero JL: Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res 2008;158:206-216.
24.
Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML: Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res 2012;46:1421-1426.
25.
Schwarz MJ, Muller N, Riedel M, Ackenheil M: The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Medical Hypotheses 2001;56:483-486.
26.
Xiong P, Zeng Y, Wan J, Huang XD, Tan DY, Lu J, Xu F, Li HY, Zhu ZX, Ma MX: The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res 2011;189:72-76.
27.
Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, Di Nicola M, Grilli A: Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011;12:13.
28.
Zhang XY, Tang W, Xiu MH, Chen da C, Yang FD, Tan YL, Wang ZR, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR: Interleukin 18 and cognitive impairment in first episode and drug naive schizophrenia versus healthy controls. Brain Behav Immun 2013;32:105-111.
29.
Martinez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, Mico JA, Fernandez M, Echevarria E, Sanjuan J, Elorza J, Gonzalez-Pinto A: Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012;137:66-72.
30.
Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B: Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res 2012;198:212-215.
31.
Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L, Rodriguez-Jimenez R, Saiz PA, Castro C, Lafuente A, Santabarbara J, Gonzalez-Pinto A, Parellada M, Rubio G, Garcia-Portilla MP, Mico JA, Bernardo M, Leza JC: Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull 2013, E-pub ahead of print.
32.
Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML: Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res 2013;147:103-109.
33.
Severance EG, Alaedini A, Yang S, Halling M, Gressitt KL, Stallings CR, Origoni AE, Vaughan C, Khushalani S, Leweke FM, Dickerson FB, Yolken RH: Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr Res 2012;138:48-53.
34.
Severance EG, Gressitt KL, Stallings CR, Origoni AE, Khushalani S, Leweke FM, Dickerson FB, Yolken RH: Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 2013;148:130-137.
35.
Hepgul N, Pariante CM, Dipasquale S, DiForti M, Taylor H, Marques TR, Morgan C, Dazzan P, Murray RM, Mondelli V: Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. Psychol Med 2012;42:1893-1901.
36.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 5. Arlington, American Psychiatric Association, 2013.
37.
Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A, Di Nicola M, Fisher H, Handley R, Marques TR, Morgan C, Navari S, Taylor H, Papadopoulos A, Aitchison KJ, Murray RM, Pariante CM: Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr Res 2010;116:234-242.
38.
Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A: Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008;65:409-415.
39.
Danese A, McEwen BS: Adverse childhood experiences, allostasis, allostatic load, and age-related disease. Physiol Behav 2012;106:29-39.
40.
Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Moller HJ, Klauss V, Schwarz MJ, Riedel M: Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121:118-124.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.